Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) by unknown
Brief  Definitive Report 
Efficient Destruction  of Human lmmunodeficiencyVirus 
in Human  Serum by Inhibiting the Protective Action 
of Complement  Factor H  and Decay Accelerating Factor 
(DAF, CD55) 
By Heribert Stoiber,* Claudia Pint&,r Antonio G. Siccardifl 
Mberto Clivio,r and Manfred E Dierich* 
From the *Institut fi~r Hygiene and Ludwig Boltzmann Institut fiir AIDS Forschung,  A-6020 
Innsbruck, Austria; *Dipartimento di Biologia e Genetica per le Scienze Mediche, Laboratorio 
Interdisciplinare di Tecnologie  Avanzate Vialba, Universitd di Milano, 20157 Milano; and 
~Dipartimento di Biologia e Tecnologia San Raffaele, 20132 Milano, Italy 
Summary 
Activation of the human complement system leads to complement deposition on human im- 
munodeficiency virus  (HIV)  and  HIV-infected  cells  without  causing efficient  complement- 
mediated lysis.  Even in the presence  of HIV-specific antibodies,  only a few particles  are de- 
stroyed,  demonstrating  that  HIV  is  intrinsically  resistant  to  human  complement.  Here  we 
report that,  in addition  to decay accelerating factor (DAF) being partially responsible,  human 
complement factor H  (CFH), a humoral negative regulator of complement activation, is most 
critical for this resistance.  In the presence of HIV-specific antibodies, sera devoid of CFH (total 
genetic deficiency or normal human serum depleted of CFH by affinity chromatography) lysed 
free virus and HIV-infected but not uninfected ceils.  In the presence ofCFH, lysis of HIV was 
only obtained when binding of CFH to gp41 was inhibited by a monoclonal antibody against a 
main CFH-binding site in gp41.  Since CFH is an abundant protein in serum,  and high local 
concentration of CFH can be obtained at the surface of HIV as the result of specific interac- 
tions  of CFH  with  the  HIV envelope,  it  is  proposed  that  the  resistance  of HIV and  HIV- 
infected cells  against complement-mediated lysis  in vivo is dependent  on DAF and CFH and 
can be overcome by suppressing this protection. Neutralization of HIV may be achieved by an- 
tibodies against DAF and, more importantly, antibodies against CFH-binding sites  on HIV en- 
velope proteins. 
H 
IV  and  HIV-infected  ceils  are  not  lysed  by human 
complement;  even  in  the  presence  of HIV-specific 
antibodies,  lysis  is  only partial  (1--4).  This  intrinsic  resis- 
tance is not due to a failure of HIV surface glycoproteins to 
interact  with  complement  proteins,  since  HIV,  HIV- 
infected  ceils,  and  purified  HIV  envelope  proteins  bind 
complement proteins with activating functions like Clq or 
Mannan binding protein  (1,  5,  6)  and trigger complement 
fixation.  Resistance  of HIV to  complement  could in part 
be  explained  by the  presence  of decay accelerating factor 
(DAF,  CD55) and CD59 on the surface of HIV; covering 
DAF  or  CD59  with  specific  antibodies  eliminated  their 
protective effect and resulted in partial lysis of lab strains by 
normal human serum  (NHS)  (7,  8).  Recently,  interaction 
of complement  factor  H  (CFH),  a  negative  regulator  of 
complement activation,  with both  envelope  glycoproteins 
of HIV-1,  gp120  and  gp41,  was  independently  described 
by Stoiber et al. and Pint6r et al.  (9-12). CFH down-regu- 
lates  the  amplification loop of complement activation and 
acts as cofactor for inactivation of C3b to iC3b (13,14).  In 
contrast to  C3b,  iC3b  does not provide further activation 
of the  complement  system,  and  as  a  consequence,  mem- 
brane  attack  complex  (MAC)  formation  does  not  occur 
(15).  Here we show that resistance  to human complement 
can be  completely overcome if DAF and  CFH  (300-500 
Ixg/ml in NHS) are set out of function. 
Materials and Methods 
CFH-depleted  Human  Serum  Was  Represented  by  Genetically 
CFH-deficient  Serum or Prepared  fiom NHS.  Lyophilized  and  ti- 
trated  human plasma  (S-1767;  Sigma  Chemical Co.,  St.  Louis, 
MO)  was dissolved  in ice-cold ultrapure  water and depleted of 
CFH by incubation with CNBr-activated Sepharose  (Pharmacia, 
Uppsala,  Sweden)  coupled with the mAb 5H5, specific for hu- 
man CFH (9). Uncoupled Sepharose beads were used as a control 
to show that depletion was due to the antibody and not to unspe- 
cific adsorption to Sepharose.  The amount of Sepharose-bound 
mAb was used in a sixfold excess as compared with the calculated 
amount  of CFH present  in  the plasma  sample.  Incubation was 
performed at 4~  for 2 h.  CFH concentration was checked after 
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ern blot. All Sepharose  supernatants were filter sterilized before 
use in cell assays. 
Purification of Antibodies from  Sera of Patients with  AIDS  and 
NHS.  IgG from sera of AIDS patients and from NHS were pu- 
rified from the pass-through  of a DEAE Affi-Gel Blue column 
(BioKad,  Richmond,  CA)  and vacuum ulrafiltration on mem- 
branes (Micro  Prodicon; Spectrum,  Houston, TX) with a  100- 
kD  cut-off,  to  eliminate transferrin.  The  AIDS  sera  used  as  a 
source of human AIDS Ig were chosen on the basis of their reac- 
tivity in ELISA assays against gp120  and gp41  (American Bio- 
technologies, Cambridge, MA). Normal sera were controlled for 
the absence of anti-env antibodies with the same method. 
Assay of Complement-dependent Cytotoxicity (CDC).  Each  ex- 
periment contained 10  s  of HIV-infected (8E5)  and,  as  control, 
noninfected CEM (American Type Culture Collection CCLl19) 
cells in protein-flee medium and four different doses  of NHS de- 
pleted ofCFH  (NHS cF"  ) as complement source (1:10, 1:20, 1: 
40,  1:80, and no complement added).  Before  being exposed to 
complement, HIV-infected and uninfected cells  were  incubated 
with 50  I*g/ml of purified human antibodies from either HIV  + 
or healthy donors for 1 h on ice. The cells were washed and re- 
suspended in duplicates in prediluted serum samples. After 1 h at 
37~  the reaction was stopped by the addition of 2.5 raN1 EGTA 
(final concentration). Cell viability was monitored by trypan blue 
exclusion and calculated on the basis of the following formula: % 
CDC =  (number of dead cells/number of dead cells  +  live cells) 
x  100. 
Complement-mediated Lysis Of HIV.  NHS or serum from a pa- 
tient with genetic CFH deficiency (CFH  a~f) (16)  (both end dilu- 
tions 1:10)  was incubated with purified antibodies isolated from 
HIV  + (Ig anti-HIV) on ice. In some cases, polyclonal antibodies 
against DAF (anti-DAF) were added (end dilution 1:100). The so- 
lutions were transferred to an ELISA plate, which was precoated 
with antibodies against p24. Constant amounts of primary isolates 
(92P,  W021,  92TH024,  IBK-0295) and the lab strain HIV-IIIB 
were added, and the mixture was incubated for 1 h at 37~  to al- 
low complement-mediated lysis of viral particles and release of p24 
in the absence of detergent. Free p24 in the supernatant, an indi- 
cator for lysis and neutralization of HIV (8,  17), bound to the an- 
tibody on the ELISA plate. After four washing cycles with PBS 
without detergent, a second antibody against p24 was added, fol- 
lowed by two further washing steps with PBS and two with PBS, 
containing 0.1% Tween 20. The ELISA was developed with biotin- 
streptavidin, and the optical density of the samples (ODsampl~) was 
measured. NP-40 was used to determine 100% lysis (ODNP40) and 
the background (ODback) by incubation of HIV with NHS with- 
out  lg anti-HlV. The  percentage of lysis was  calculated by the 
following  formula:  (ODsample-ODback/ODNP40-ODback)  X  100. 
The experiments were performed in duplicate. 
Results  and Discussion 
To test the hypothesis that direct binding of CFH to the 
envelope of HIV-1  might protect  the virus from  destruc- 
tion by human serum,  8E5  cells, chronically infected with 
HIV (18), and noninfected CEM cells were pretreated with 
Ig obtained from HIV + or healthy individuals and exposed 
to NHS cFH-. As shown in Fig.  1,  only HIV-infected cells 
were  susceptible to  CDC.  Furthermore,  CDC  was strictly 
dependent on the use of NHSCFH-; application of NHS in- 
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Figure  1.  Assay  of CDC.  H1V + (8E5) and uninfected  cells (CEM) 
were  incubated  with CFH-depleted serum containing purified  Ig from 
HIV  + sera (Ig anti-HIV) or Ig from NHS, and CDC was determined. 
mally the protective role of CFH,  NHS cFH- was reconsti- 
tuted with increasing amounts of CFH.  50% protection of 
HIV-infected cells could be obtained by the addition of 0-~8 
Ixg CFH/ml  (Fig.  2),  corresponding to a  reconstitution of 
~5%  of the normal CFH concentration in plasma. 
In the  next set  of experiments,  free  viral particles  from 
different  primary  isolates,  92RW021,  92TH024,  IBK- 
0295,  and lab strain HIV-IIIB, were  incubated with NHS 
or NHS cFH  ,  each in combination with different antibod- 
ies.  In accordance with Spear et al.  (4),  in the presence  of 
HIV-specific  antibodies  and  NHS  complement-depen- 
dent virolysis, up to 30% lysis in the case of HIV-IIIB was 
obtained. Primary isolates were more resistant to lysis, that 
is, only 12% lysis was obtained with IBK-0295, a virus iso- 
lated from an Innsbruck patient and passaged only once for 
these experiments. Therefore,  88% of this isolate was unaf- 
fected by human complement (Fig. 3). Lysis could be con- 
siderably increased by the presence  of an antibody against 
DAF,  eliminating the  DAF-mediated anticomplement ef- 
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Figure  2.  Effect of addition  of CFH  to  CFH-depleted serum.  The 
CDC decreased as increasing amounts of CFH were added. The percent- 
ages of CDC were determined as described in Materials and Methods. 
308  Role of CFH and DAF in Resistance of HIV against Complement Figure 3.  Lysis  of cell-free HIV by human serum. Different HIV iso- 
lates (the lab strain HIV-IIIB and three primary isolates) were incubated 
with NHS or serum from a patient with total CFH  def in the presence of 
purified lgG from sera of HIV + individuals (Ig anti-HIV). In some assays, 
anti-DAF antibodies were added as indicated. The percentage of comple- 
ment-mediated lysis  was monitored by measuring free p24 in the superna- 
tant as described in Materials and Methods. 
and  serum  derived  from  a  patient  with  total  CFH  d~f re- 
sulted in release of 85%  of total p24, indicating a very effi- 
cient inactivation of HIV.  These  findings  clearly demon- 
strate  that  CFH  is  the  main  contributor  to  resistance  of 
HIV  against lysis by human  complement.  Interestingly, a 
comparable  defense  strategy  was  shown  for  streptococci, 
which  bind  CFH  on  their surface  protein M  (19).  Com- 
bining  CFH  def and  anti-DAF  in  the  presence  of Ig  anti- 
HIV,  nearly all free HIV particles were destroyed through 
the lytic action of human  complement  (Fig. 3).  To  prove 
directly whether binding of CFH  to  gp41  was  critical for 
CFH-mediated protection,  the  different  HIV  strains were 
tested in  the  presence  of mAb  2F5.  This  antibody covers 
the  ELDKWAS  motif in  gp41  (aa 665-671  in  HIV-IIIB) 
and is known  to  neutralize HIV in vitro  (17);  in addition, 
this site in gp41 was described as a binding region for factor 
H  (8-11). As shown in Fig. 3, incubation of HIV with 2F5 
and  addition  of NHS  in  combination  with  Ig  anti-HIV 
lead to  the  destruction  of ~60%  of available HIV.  Obvi- 
ously, the CFH-mediated protection of HIV from comple- 
ment-dependent  lysis  was  abrogated  because  of interfer- 
ence  by mAb 2F5  with  CFH  binding to  the ELDKWAS 
motif of the viral envelope protein. 
These results suggest that DAF as part of the viral mem- 
brane find exogenous CFH secondarily attached to the HIV 
envelope proteins together are sufficient to explain the effi- 
cient,  intrinsic  resistance  of HIV  to  human  complement. 
Overcoming these two barriers should be appropriate goals 
for new vaccine strategies. By activating complement, HIV 
coats itself with C3,  thus enhancing its infectivity and pro- 
viding, for example, for follicular localization (20-24) while 
avoiding complement-mediated destruction via complement 
control  proteins  DAF  and  CFH.  This  mechanism  might 
represent a general strategy also used by other complement- 
resistant human retroviruses. 
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